drug
deuruxolitinib phosphate
Marketedupdated 3mo agoby Sun Pharmaceutical Industries Ltd
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jul 25, 2029
~3.0 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (6)
- Oct 10, 2044method-of-use (U-3976)US 12364699
- May 10, 2044compositionUS 12247034
- Aug 11, 2042method-of-use (U-3976)US 12285432
- May 21, 2041formulationUS 11919907
- May 4, 2037method-of-use (U-3976)US 10561659
- May 4, 2037method-of-use (U-3976)US 12076323
FDA exclusivities (1)
- Jul 25, 2029NCENew Chemical Entity (5y)3.0y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that